MaxCyte, Inc.

NasdaqGS:MXCT Stock Report

Market Cap: US$432.9m

MaxCyte Valuation

Is MXCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MXCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MXCT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MXCT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MXCT?

Key metric: As MXCT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MXCT. This is calculated by dividing MXCT's market cap by their current revenue.
What is MXCT's PS Ratio?
PS Ratio9.5x
SalesUS$45.60m
Market CapUS$432.86m

Price to Sales Ratio vs Peers

How does MXCT's PS Ratio compare to its peers?

The above table shows the PS ratio for MXCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.6x
CDXC ChromaDex
4.5x18.1%US$416.4m
QTRX Quanterix
3.1x14.4%US$403.7m
SLGC Standard BioTools
4.8x16.4%US$396.2m
CYRX Cryoport
1.7x7.0%US$389.0m
MXCT MaxCyte
9.5x21.3%US$345.6m

Price-To-Sales vs Peers: MXCT is expensive based on its Price-To-Sales Ratio (9.5x) compared to the peer average (3.6x).

Price to Sales Ratio vs Industry

How does MXCT's PS Ratio compare vs other companies in the US Life Sciences Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.6x2.4%US$1.68b
ATLN Atlantic International
0.6xn/aUS$240.70m
NOTV Inotiv
0.2x6.0%US$117.85m
SNCE Science 37 Holdings
0.6x17.5%US$34.67m
MXCT 9.5xIndustry Avg. 3.5xNo. of Companies9PS02.85.68.411.214+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MXCT is expensive based on its Price-To-Sales Ratio (9.5x) compared to the US Life Sciences industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is MXCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MXCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.5x
Fair PS Ratio5x

Price-To-Sales vs Fair Ratio: MXCT is expensive based on its Price-To-Sales Ratio (9.5x) compared to the estimated Fair Price-To-Sales Ratio (5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MXCT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.11
US$8.17
+98.8%
19.9%US$9.80US$6.54n/a2
Dec ’25US$3.55
US$8.24
+132.2%
20.6%US$9.94US$6.54n/a2
Nov ’25US$3.77
US$8.25
+118.9%
20.7%US$9.96US$6.54n/a2
Oct ’25US$3.70
US$6.97
+88.4%
39.8%US$9.74US$4.20n/a2
Sep ’25US$4.32
US$6.97
+61.4%
39.8%US$9.74US$4.20n/a2
Aug ’25US$4.57
US$6.99
+53.0%
40.8%US$9.85US$4.14n/a2
Jul ’25US$3.83
US$6.91
+80.4%
40.1%US$9.68US$4.14n/a2
Jun ’25US$4.48
US$6.94
+55.0%
40.4%US$9.75US$4.14n/a2
Oct ’24US$3.12
US$9.39
+201.0%
6.5%US$10.00US$8.78US$3.702
Sep ’24US$3.70
US$9.39
+153.8%
6.5%US$10.00US$8.78US$4.322
Aug ’24US$4.50
US$10.76
+139.2%
7.0%US$11.51US$10.02US$4.572
Jul ’24US$4.59
US$10.70
+133.1%
7.6%US$11.51US$9.89US$3.832
Jun ’24US$4.14
US$10.67
+157.8%
7.8%US$11.51US$9.84US$4.482
May ’24US$4.85
US$12.05
+148.5%
6.5%US$12.84US$11.27US$3.782
Apr ’24US$4.95
US$12.05
+143.5%
6.5%US$12.84US$11.27US$4.192
Mar ’24US$4.43
US$11.98
+170.4%
3.2%US$12.36US$11.60US$4.712
Feb ’24US$5.69
US$11.98
+110.6%
3.2%US$12.36US$11.60US$5.192
Jan ’24US$5.46
US$12.06
+120.8%
2.5%US$12.36US$11.75US$4.702
Dec ’23US$6.17
US$11.93
+93.3%
3.6%US$12.36US$11.49US$4.982

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 19:52
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MaxCyte, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Matthew HewittCraig-Hallum Capital Group LLC
Paul CuddonNumis Securities Ltd.